Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 -

- Clinical data update expected in Q2 2025 -